abrdn Life Sciences Investors

HQL

Market cap $485M

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

PHILADELPHIA, Feb. 10, 2026 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on February 27, 2026 to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on March 31, 2026 to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026).

If you're wondering whether the rally in tech stocks is fading, well, it is.

abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL's income-focused strategy relies on net realized gains, supporting robust distributions but exposing NAV to downside risk in weak markets. Biotech dominates HQL's portfolio (82.7%), with top holdings like AMGN and REG, and no direct leverage, but interest rate sensitivity remains.

PHILADELPHIA, Jan. 12, 2026 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on January 12, 2026, on a per share basis to all shareholders of record as of December 31, 2025 (ex-dividend date December 31, 2025). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) which paid on January 12, 2026, to all shareholders of record as of November 21, 2025 (ex-dividend date November 21, 2025).

PHILADELPHIA , Nov. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on November 28, 2025 to all shareholders of record as of November 21, 2025 (ex-dividend date November 21, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on January 12, 2026, to all shareholders of record as of November 21, 2025 (ex-dividend date November 21, 2025).

abrdn Life Sciences Investors remains a buy for high-yield seekers, offering a 10.1% dividend yield and diversified healthcare exposure. HQL trades at a 7.92% discount to NAV, with its share price historically benefiting from lower interest rates and sector growth initiatives. The fund's focus on income, option writing, and heavy biotech allocation limits long-term capital appreciation and has led to underperformance versus peers like THQ and THW.

PHILADELPHIA , Sept. 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF)  (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2025, on a per share basis to all shareholders of record as of September 23, 2025 (ex-dividend date September 23, 2025).

HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to underperformance versus broader healthcare ETFs and higher sensitivity to sector weakness. Dividend coverage remains consistent despite recent earnings volatility, but distributions are not tax-efficient and rely on capital gains.

PHILADELPHIA , Aug. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 29, 2025 to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on September 30, 2025, to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025).